View Future GrowthUBI Pharma 과거 순이익 실적과거 기준 점검 2/6UBI Pharma은 연평균 66.9%의 비율로 수입이 증가해 온 반면, Biotechs 산업은 수입이 21.8% 증가했습니다. 매출은 연평균 10.3%의 비율로 증가했습니다. UBI Pharma의 자기자본이익률은 0.07%이고 순이익률은 0.1%입니다.핵심 정보66.95%순이익 성장률67.03%주당순이익(EPS) 성장률Biotechs 산업 성장률12.22%매출 성장률10.31%자기자본이익률0.069%순이익률0.12%최근 순이익 업데이트31 Dec 2023최근 과거 실적 업데이트Reported Earnings • Apr 20Full year 2023 earnings released: EPS: NT$0.01 (vs NT$0.41 in FY 2022)Full year 2023 results: EPS: NT$0.01 (down from NT$0.41 in FY 2022). Revenue: NT$648.6m (up 2.3% from FY 2022). Net income: NT$803.0k (down 98% from FY 2022). Profit margin: 0.1% (down from 7.4% in FY 2022). The decrease in margin was driven by higher expenses.Reported Earnings • Aug 17First half 2023 earnings released: EPS: NT$0.12 (vs NT$0.18 in 1H 2022)First half 2023 results: EPS: NT$0.12 (down from NT$0.18 in 1H 2022). Revenue: NT$335.7m (up 5.2% from 1H 2022). Net income: NT$13.8m (down 28% from 1H 2022). Profit margin: 4.1% (down from 6.1% in 1H 2022). The decrease in margin was driven by higher expenses.Reported Earnings • Apr 22Full year 2022 earnings released: EPS: NT$0.43 (vs NT$0.23 in FY 2021)Full year 2022 results: EPS: NT$0.43 (up from NT$0.23 in FY 2021). Revenue: NT$633.8m (down 1.6% from FY 2021). Net income: NT$47.2m (up 111% from FY 2021). Profit margin: 7.4% (up from 3.5% in FY 2021). The increase in margin was driven by lower expenses.Reported Earnings • Aug 19First half 2022 earnings released: EPS: NT$0.18 (vs NT$0.43 loss in 1H 2021)First half 2022 results: EPS: NT$0.18 (up from NT$0.43 loss in 1H 2021). Revenue: NT$319.0m (up 9.3% from 1H 2021). Net income: NT$19.3m (up NT$58.6m from 1H 2021). Profit margin: 6.1% (up from net loss in 1H 2021). The move to profitability was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 98% per year but the company’s share price has only increased by 29% per year, which means it is significantly lagging earnings growth.Reported Earnings • Aug 18First half 2021 earnings released: NT$0.43 loss per share (vs NT$1.05 loss in 1H 2020)The company reported a solid first half result with reduced losses, improved revenues and improved control over expenses. First half 2021 results: Revenue: NT$291.8m (up 29% from 1H 2020). Net loss: NT$39.2m (loss narrowed 56% from 1H 2020). Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has increased by 81% per year, which means it is tracking significantly ahead of earnings growth.모든 업데이트 보기Recent updatesReported Earnings • Apr 20Full year 2023 earnings released: EPS: NT$0.01 (vs NT$0.41 in FY 2022)Full year 2023 results: EPS: NT$0.01 (down from NT$0.41 in FY 2022). Revenue: NT$648.6m (up 2.3% from FY 2022). Net income: NT$803.0k (down 98% from FY 2022). Profit margin: 0.1% (down from 7.4% in FY 2022). The decrease in margin was driven by higher expenses.Valuation Update With 7 Day Price Move • Apr 18Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to NT$22.80, the stock trades at a trailing P/E ratio of 64.6x. Average trailing P/E is 48x in the Biotechs industry in Taiwan. Total loss to shareholders of 45% over the past year.New Risk • Apr 17New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: NT$3.20b (US$98.5m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Profit margins are more than 30% lower than last year (6.4% net profit margin). Shareholders have been diluted in the past year (2.2% increase in shares outstanding). Market cap is less than US$100m (NT$3.20b market cap, or US$98.5m).공시 • Mar 20UBI Pharma Inc., Annual General Meeting, Jun 06, 2024UBI Pharma Inc., Annual General Meeting, Jun 06, 2024.New Risk • Feb 27New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Profit margins are more than 30% lower than last year (6.4% net profit margin). Shareholders have been diluted in the past year (2.2% increase in shares outstanding).New Risk • Dec 16New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.2% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Profit margins are more than 30% lower than last year (6.4% net profit margin). Shareholders have been diluted in the past year (2.2% increase in shares outstanding).Reported Earnings • Aug 17First half 2023 earnings released: EPS: NT$0.12 (vs NT$0.18 in 1H 2022)First half 2023 results: EPS: NT$0.12 (down from NT$0.18 in 1H 2022). Revenue: NT$335.7m (up 5.2% from 1H 2022). Net income: NT$13.8m (down 28% from 1H 2022). Profit margin: 4.1% (down from 6.1% in 1H 2022). The decrease in margin was driven by higher expenses.New Risk • Aug 12New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 6.4% Last year net profit margin: 12% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. This is currently the only risk that has been identified for the company.Buying Opportunity • Jul 13Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 19%. The fair value is estimated to be NT$44.72, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Meanwhile, the company has become profitable.Buying Opportunity • Jun 16Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 22%. The fair value is estimated to be NT$44.79, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Meanwhile, the company has become profitable.Reported Earnings • Apr 22Full year 2022 earnings released: EPS: NT$0.43 (vs NT$0.23 in FY 2021)Full year 2022 results: EPS: NT$0.43 (up from NT$0.23 in FY 2021). Revenue: NT$633.8m (down 1.6% from FY 2021). Net income: NT$47.2m (up 111% from FY 2021). Profit margin: 7.4% (up from 3.5% in FY 2021). The increase in margin was driven by lower expenses.Valuation Update With 7 Day Price Move • Dec 05Investor sentiment improved over the past weekAfter last week's 18% share price gain to NT$55.60, the stock trades at a trailing P/E ratio of 76.5x. Average trailing P/E is 40x in the Biotechs industry in Taiwan. Total returns to shareholders of 509% over the past three years.Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Director Yau-Huei Wei was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Valuation Update With 7 Day Price Move • Oct 28Investor sentiment improved over the past weekAfter last week's 25% share price gain to NT$39.40, the stock trades at a trailing P/E ratio of 54.2x. Average trailing P/E is 35x in the Biotechs industry in Taiwan. Total returns to shareholders of 314% over the past three years.Reported Earnings • Aug 19First half 2022 earnings released: EPS: NT$0.18 (vs NT$0.43 loss in 1H 2021)First half 2022 results: EPS: NT$0.18 (up from NT$0.43 loss in 1H 2021). Revenue: NT$319.0m (up 9.3% from 1H 2021). Net income: NT$19.3m (up NT$58.6m from 1H 2021). Profit margin: 6.1% (up from net loss in 1H 2021). The move to profitability was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 98% per year but the company’s share price has only increased by 29% per year, which means it is significantly lagging earnings growth.Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Director Yau-Huei Wei was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Aug 18First half 2021 earnings released: NT$0.43 loss per share (vs NT$1.05 loss in 1H 2020)The company reported a solid first half result with reduced losses, improved revenues and improved control over expenses. First half 2021 results: Revenue: NT$291.8m (up 29% from 1H 2020). Net loss: NT$39.2m (loss narrowed 56% from 1H 2020). Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has increased by 81% per year, which means it is tracking significantly ahead of earnings growth.매출 및 비용 세부 내역UBI Pharma가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이TPEX:6562 매출, 비용 및 순이익 (TWD Millions)날짜매출순이익일반관리비연구개발비31 Dec 236491939930 Sep 23650219211530 Jun 23651429013131 Mar 23642449114131 Dec 22634479215230 Sep 22660649214030 Jun 22686819112831 Mar 22665528813731 Dec 21644228514530 Sep 21577-110714930 Jun 21510-2412915331 Mar 21484-4914014531 Dec 20458-7415213630 Sep 20467-14913716730 Jun 20476-22312219731 Mar 20478-23312720531 Dec 19480-24213321330 Sep 19459-24212922030 Jun 19438-24212422831 Mar 19431-24110723931 Dec 18424-2419025030 Sep 18412-2138122030 Jun 18400-1857319131 Mar 18366-1766617931 Dec 17333-1675916830 Sep 17335-2045520630 Jun 17337-2415124431 Mar 17347-2335224331 Dec 16358-2265324130 Sep 16389-1355418730 Jun 16421-435513431 Mar 16417-215410631 Dec 154132547831 Dec 14409394229양질의 수익: 6562는 고품질 수익을 보유하고 있습니다.이익 마진 증가: 6562의 현재 순 이익률 (0.1%)은 지난해 (7.4%)보다 낮습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: 6562는 지난 5년 동안 흑자전환하며 연평균 66.9%의 수익 성장을 기록했습니다.성장 가속화: 6562은 지난 1년 동안 수익이 감소하여 5년 평균과 비교할 수 없습니다.수익 대 산업: 6562은 지난 1년 동안 수익이 감소(-98.3%)하여 Biotechs 업계 평균(12.2%)과 비교하기 어렵습니다.자기자본이익률높은 ROE: 6562의 자본 수익률(0.07%)은 낮음으로 평가됩니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2024/05/12 16:51종가2024/05/10 00:00수익2023/12/31연간 수익2023/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스UBI Pharma Inc.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
Reported Earnings • Apr 20Full year 2023 earnings released: EPS: NT$0.01 (vs NT$0.41 in FY 2022)Full year 2023 results: EPS: NT$0.01 (down from NT$0.41 in FY 2022). Revenue: NT$648.6m (up 2.3% from FY 2022). Net income: NT$803.0k (down 98% from FY 2022). Profit margin: 0.1% (down from 7.4% in FY 2022). The decrease in margin was driven by higher expenses.
Reported Earnings • Aug 17First half 2023 earnings released: EPS: NT$0.12 (vs NT$0.18 in 1H 2022)First half 2023 results: EPS: NT$0.12 (down from NT$0.18 in 1H 2022). Revenue: NT$335.7m (up 5.2% from 1H 2022). Net income: NT$13.8m (down 28% from 1H 2022). Profit margin: 4.1% (down from 6.1% in 1H 2022). The decrease in margin was driven by higher expenses.
Reported Earnings • Apr 22Full year 2022 earnings released: EPS: NT$0.43 (vs NT$0.23 in FY 2021)Full year 2022 results: EPS: NT$0.43 (up from NT$0.23 in FY 2021). Revenue: NT$633.8m (down 1.6% from FY 2021). Net income: NT$47.2m (up 111% from FY 2021). Profit margin: 7.4% (up from 3.5% in FY 2021). The increase in margin was driven by lower expenses.
Reported Earnings • Aug 19First half 2022 earnings released: EPS: NT$0.18 (vs NT$0.43 loss in 1H 2021)First half 2022 results: EPS: NT$0.18 (up from NT$0.43 loss in 1H 2021). Revenue: NT$319.0m (up 9.3% from 1H 2021). Net income: NT$19.3m (up NT$58.6m from 1H 2021). Profit margin: 6.1% (up from net loss in 1H 2021). The move to profitability was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 98% per year but the company’s share price has only increased by 29% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Aug 18First half 2021 earnings released: NT$0.43 loss per share (vs NT$1.05 loss in 1H 2020)The company reported a solid first half result with reduced losses, improved revenues and improved control over expenses. First half 2021 results: Revenue: NT$291.8m (up 29% from 1H 2020). Net loss: NT$39.2m (loss narrowed 56% from 1H 2020). Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has increased by 81% per year, which means it is tracking significantly ahead of earnings growth.
Reported Earnings • Apr 20Full year 2023 earnings released: EPS: NT$0.01 (vs NT$0.41 in FY 2022)Full year 2023 results: EPS: NT$0.01 (down from NT$0.41 in FY 2022). Revenue: NT$648.6m (up 2.3% from FY 2022). Net income: NT$803.0k (down 98% from FY 2022). Profit margin: 0.1% (down from 7.4% in FY 2022). The decrease in margin was driven by higher expenses.
Valuation Update With 7 Day Price Move • Apr 18Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to NT$22.80, the stock trades at a trailing P/E ratio of 64.6x. Average trailing P/E is 48x in the Biotechs industry in Taiwan. Total loss to shareholders of 45% over the past year.
New Risk • Apr 17New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: NT$3.20b (US$98.5m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Profit margins are more than 30% lower than last year (6.4% net profit margin). Shareholders have been diluted in the past year (2.2% increase in shares outstanding). Market cap is less than US$100m (NT$3.20b market cap, or US$98.5m).
공시 • Mar 20UBI Pharma Inc., Annual General Meeting, Jun 06, 2024UBI Pharma Inc., Annual General Meeting, Jun 06, 2024.
New Risk • Feb 27New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Profit margins are more than 30% lower than last year (6.4% net profit margin). Shareholders have been diluted in the past year (2.2% increase in shares outstanding).
New Risk • Dec 16New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.2% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Profit margins are more than 30% lower than last year (6.4% net profit margin). Shareholders have been diluted in the past year (2.2% increase in shares outstanding).
Reported Earnings • Aug 17First half 2023 earnings released: EPS: NT$0.12 (vs NT$0.18 in 1H 2022)First half 2023 results: EPS: NT$0.12 (down from NT$0.18 in 1H 2022). Revenue: NT$335.7m (up 5.2% from 1H 2022). Net income: NT$13.8m (down 28% from 1H 2022). Profit margin: 4.1% (down from 6.1% in 1H 2022). The decrease in margin was driven by higher expenses.
New Risk • Aug 12New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 6.4% Last year net profit margin: 12% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. This is currently the only risk that has been identified for the company.
Buying Opportunity • Jul 13Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 19%. The fair value is estimated to be NT$44.72, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Meanwhile, the company has become profitable.
Buying Opportunity • Jun 16Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 22%. The fair value is estimated to be NT$44.79, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Meanwhile, the company has become profitable.
Reported Earnings • Apr 22Full year 2022 earnings released: EPS: NT$0.43 (vs NT$0.23 in FY 2021)Full year 2022 results: EPS: NT$0.43 (up from NT$0.23 in FY 2021). Revenue: NT$633.8m (down 1.6% from FY 2021). Net income: NT$47.2m (up 111% from FY 2021). Profit margin: 7.4% (up from 3.5% in FY 2021). The increase in margin was driven by lower expenses.
Valuation Update With 7 Day Price Move • Dec 05Investor sentiment improved over the past weekAfter last week's 18% share price gain to NT$55.60, the stock trades at a trailing P/E ratio of 76.5x. Average trailing P/E is 40x in the Biotechs industry in Taiwan. Total returns to shareholders of 509% over the past three years.
Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Director Yau-Huei Wei was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Valuation Update With 7 Day Price Move • Oct 28Investor sentiment improved over the past weekAfter last week's 25% share price gain to NT$39.40, the stock trades at a trailing P/E ratio of 54.2x. Average trailing P/E is 35x in the Biotechs industry in Taiwan. Total returns to shareholders of 314% over the past three years.
Reported Earnings • Aug 19First half 2022 earnings released: EPS: NT$0.18 (vs NT$0.43 loss in 1H 2021)First half 2022 results: EPS: NT$0.18 (up from NT$0.43 loss in 1H 2021). Revenue: NT$319.0m (up 9.3% from 1H 2021). Net income: NT$19.3m (up NT$58.6m from 1H 2021). Profit margin: 6.1% (up from net loss in 1H 2021). The move to profitability was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 98% per year but the company’s share price has only increased by 29% per year, which means it is significantly lagging earnings growth.
Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Director Yau-Huei Wei was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Aug 18First half 2021 earnings released: NT$0.43 loss per share (vs NT$1.05 loss in 1H 2020)The company reported a solid first half result with reduced losses, improved revenues and improved control over expenses. First half 2021 results: Revenue: NT$291.8m (up 29% from 1H 2020). Net loss: NT$39.2m (loss narrowed 56% from 1H 2020). Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has increased by 81% per year, which means it is tracking significantly ahead of earnings growth.